Multiple Myeloma Drug Tested
Phase III clinical trials of a multiple myeloma drug have been completed (INN ixazomib). The drug has been developed by a well-known pharmaceutical company Takeda. Its effectiveness in therapy of relapsed and resistant multiple myeloma has been confirmed. Patient survival is significantly increased with the new drug.
The study began in 2014 and involved 722 patients with relapsed or therapy resistant multiple myeloma. They received (in different groups) ixazomib with antineoplastid lanalidomide and glucocorticoid dexamethasone or placebo plus lenalidomide and dexamethasone.
Experimental oral drug ixazomib is the first in class protease inhibitor preventing degradation of regulatory proteins. It decreases expression of nuclear factor NF-kB, which prevents apoptosis of tumor cells.